Industry Trends

Interpreting what the Inflation Reduction Act could mean for biopharma.

How technology will play a big role in advancing pharma approaches in patient support.

As new channels enter healthcare conversation mix, engagement strategies are changing.

An evolving job market has forced life sciences companies to respond.

The steps companies can take now to better protect themselves and their data.

Baker spoke on topics ranging from pricing, access, the war for talent, and other key areas that are impacting pharma companies.

Personalized medicine continued its growth over the past year and became one of the most talked about topics in the life sciences industry.

Top industry experts weigh in on what the new year holds for the pharma industry.

Over the past year, the life sciences industry has experienced a variety of important innovations, while also facing an unstable economy. These factors were clearly on readers minds and helped shape the top stories of the year.

Michael Ku, VP of global clinical supply at Pfizer, shares insights for the c-suite as well as reveals behind-the-scenes insight into Pfizer’s ability to deliver a COVID-19 vaccine swiftly.

Lang spoke with Pharm Exec about how recent market conditions impacted pharma this year and how things may change in the coming year.

Webinar Date/Time: Thu, Dec 8, 2022 2:00 PM EST

Webinar Date/Time: Tuesday, Dec 6, 2022, 11am PT | 2pm ET

A shift in mindset to the experiment itself could lead the way.

Pharma companies need to rethink their strategies to ensure that they hire the best available talent in today's market.

With more people working from home, employers should rethink how cost-of-living impacts salary negotiations.

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

How pharma companies can make sure their corporate strategy in ESG is appealing to younger generations—and aligns with the issues this large segment of sustainability investors care about most.

The pharma industry is beginning to perform better with environmental, social, and governance (ESG).

How one company in particular has adjusted its internal and customer-facing strategies in compliance training amid today’s heightened business-risk climate.

Major stakeholders—including policymakers, public-private interests, and academia—are increasingly embracing the potential of proteomics technology in reshaping diagnostics and patient care.

Pharma companies may benefit from meeting challenges and embracing small molecule drug discovery.

Dr. Kyle Flanigan, Ph.D., discusses the benefits of an oral COVID-19 vaccine.

Corrigan discusses the importance of a patient-centric approach.

Outlook for orphan PRMA environment in the US, EU4, and UK.